Microbiologics, Inc., the leading global provider of biomaterial controls, announced today that it has acquired Micromyx, a Michigan-based commercial microbiology laboratory. Micromyx is a recognized leader in the research, development, and registration of new antimicrobial agents for clients in the pharmaceutical, biotechnology and animal health industries. The company was founded in 2004 by infectious disease scientists with extensive experience and proven success in bringing new anti-infective drugs to market.

Microbiologics is a global leader in the production, preservation and manipulation of biological materials. The company partners with organizations to co-create solutions for diagnostic assay development, drug development, vaccine screening, quality control, proficiency testing, and more. Company officials said this acquisition complements their existing microbial and viral products and services.

“The expertise Micromyx has in antimicrobial R&D broadens our portfolio of solutions for pharmaceutical and biotechnology clients and allows us to support their drug development needs from discovery through commercialization,” Microbiologics Chief Executive Officer, Brad Goskowicz, commented. “With each engagement we apply our inventive spirit, deep expertise, vast resources and unparalleled support to create the best products and services for our fellow scientists.”

Micromyx Chief Scientific Officer, Chris Pillar, Ph.D., said, “Joining the Microbiologics team will help us continue to grow and expand our services as we aim to fulfill our shared mission of protecting the health and safety of people around the world through continuous scientific innovation.” Dr. Pillar earned his Ph.D. in Microbiology from Wayne State University. His professional career includes serving as the Senior Scientist for the Anti-Infectives Services team at Eurofins Medinet.